Cardiovascular Diseases – Page 2

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

9 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment

10 months ago talkbio0Tagged ARMGO, biotech company, Cardiovascular Diseases, Changing, Heart failure, Leadership, Pharma, Rycals, RyCarma, skeletal muscle diseases

RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.

Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol

10 months ago talkbio0Tagged ANGPTL4, Cardiovascular Diseases, cholesterol, MAR001, Marea Therapeutics, Monoclonal Antibodies, Phase 2 Clinical Trials, Remnant

Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial

Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease

10 months ago talkbio0Tagged Artificial Intelligence, biotech, Cardiovascular Diseases, Computational Technique, Diabetes, Drug Development, Nordisk, Obesity, Valo Health

Novo Nordisk, Valo Health, AI, Obesity, Type 2 Diabetes, Cardiovascular Disease, Drug Development, Computational Biotech

AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy

1 year ago talkbio0Tagged AstraZeneca, Cardiovascular Diseases, Dosage Forms, GZMH gene, Investments, Lipid-lowering therapy, Lp(a ) disruptor, Pharmaceutical Group

AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment

Novartis Expands Leqvio’s Potential After Successful Phase III Study Demonstrates Significant Cholesterol Reduction

1 year ago talkbio0Tagged Atherosclerosis, Cardiovascular Diseases, cholesterol, inclisiran, LDL-C, Leqvio, Novartis, Phase 3 Clinical Trials

Novartis, Leqvio, inclisiran, cholesterol reduction, Phase III study, ASCVD, LDL-C, cardiovascular disease

Pfizer and Flagship’s Quotient Therapeutics Collaborate to Identify Novel Targets for Cardiovascular and Renal Diseases

1 year ago talkbio0Tagged Cardiovascular Diseases, Drug Development, Flagship, Kidney Diseases, Partnership, Pfizer, Pioneering, somatic genomics

Pfizer, Flagship Pioneering, Quotient Therapeutics, cardiovascular diseases, renal diseases, somatic genomics, drug development, partnership

NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations

1 year ago talkbio0Tagged Cardiovascular Diseases, CETP protein, human, Familial hypercholesterolemia - heterozygous, Heterozygote, High Density Lipoprotein Cholesterol, Hypercholesterolemia, Familial, Inhibitor, LDL Cholesterol Lipoproteins, NewAmsterdam Pharma, Obicetrapib, Phase 3 Clinical Trials

NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease